A sensitive detection method for WPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction

Alessandro Pancrazzi, Paola Guglielmelli, Vanessa Ponziani, Gaetano Bergamaschi, Alberto Bosi, Giovanni Barosi, Alessandro M. Vannucchi

Research output: Contribution to journalArticle

Abstract

Acquired mutations in the juxtamembrane region of MPL (W515K or W515L), the receptor for thrombo-poietin, have been described in patients with primary myelofibrosis or essential thrombocythemia, which are chronic myeloproliferative disorders. We have developed a real-time polymerase chain reaction assay for the detection and quantification of MPL mutations that is based on locked nucleic acid fluorescent probes. Mutational analysis was performed using DNA from granulocytes. Reference curves were obtained using cloned fragments of MPL containing either the wild-type or mutated sequence; the predicted sensitivity level was at least 0.1% mutant allele in a wild-type background. None of the 60 control subjects presented with a MPLW515L/K mutation. Of 217 patients with myelofibrosis, 19 (8.7%) harbored the MPLW515 mutation, 10 (52.6%) with the W515L allele. In one case, both the W515L and W515K alleles were detected by real-time polymerase chain reaction. By comparing results obtained with conventional sequencing, no erroneous genotype attribution using real-time polymerase chain reaction was found, whereas one patient considered wild type according to sequence analysis actually harbored a low W515L allele burden. This is a simple, sensitive, and cost-effective procedure for large-scale screening of the MPLW515L/K mutation in patients suspected to have a myeloproliferative disorder. It can also provide a quantitative estimate of mutant allele burden that might be useful for both patient prognosis and monitoring response to therapy.

Original languageEnglish
Pages (from-to)435-441
Number of pages7
JournalJournal of Molecular Diagnostics
Volume10
Issue number5
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Nucleic Acid Probes
Myeloproliferative Disorders
Real-Time Polymerase Chain Reaction
Alleles
Mutation
Essential Thrombocythemia
Primary Myelofibrosis
Physiologic Monitoring
Fluorescent Dyes
Granulocytes
Sequence Analysis
Genotype
locked nucleic acid
Costs and Cost Analysis
DNA

ASJC Scopus subject areas

  • Molecular Medicine
  • Pathology and Forensic Medicine

Cite this

A sensitive detection method for WPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. / Pancrazzi, Alessandro; Guglielmelli, Paola; Ponziani, Vanessa; Bergamaschi, Gaetano; Bosi, Alberto; Barosi, Giovanni; Vannucchi, Alessandro M.

In: Journal of Molecular Diagnostics, Vol. 10, No. 5, 09.2008, p. 435-441.

Research output: Contribution to journalArticle

Pancrazzi, Alessandro ; Guglielmelli, Paola ; Ponziani, Vanessa ; Bergamaschi, Gaetano ; Bosi, Alberto ; Barosi, Giovanni ; Vannucchi, Alessandro M. / A sensitive detection method for WPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. In: Journal of Molecular Diagnostics. 2008 ; Vol. 10, No. 5. pp. 435-441.
@article{ae404f013b1b4295b82187a61919f91b,
title = "A sensitive detection method for WPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction",
abstract = "Acquired mutations in the juxtamembrane region of MPL (W515K or W515L), the receptor for thrombo-poietin, have been described in patients with primary myelofibrosis or essential thrombocythemia, which are chronic myeloproliferative disorders. We have developed a real-time polymerase chain reaction assay for the detection and quantification of MPL mutations that is based on locked nucleic acid fluorescent probes. Mutational analysis was performed using DNA from granulocytes. Reference curves were obtained using cloned fragments of MPL containing either the wild-type or mutated sequence; the predicted sensitivity level was at least 0.1{\%} mutant allele in a wild-type background. None of the 60 control subjects presented with a MPLW515L/K mutation. Of 217 patients with myelofibrosis, 19 (8.7{\%}) harbored the MPLW515 mutation, 10 (52.6{\%}) with the W515L allele. In one case, both the W515L and W515K alleles were detected by real-time polymerase chain reaction. By comparing results obtained with conventional sequencing, no erroneous genotype attribution using real-time polymerase chain reaction was found, whereas one patient considered wild type according to sequence analysis actually harbored a low W515L allele burden. This is a simple, sensitive, and cost-effective procedure for large-scale screening of the MPLW515L/K mutation in patients suspected to have a myeloproliferative disorder. It can also provide a quantitative estimate of mutant allele burden that might be useful for both patient prognosis and monitoring response to therapy.",
author = "Alessandro Pancrazzi and Paola Guglielmelli and Vanessa Ponziani and Gaetano Bergamaschi and Alberto Bosi and Giovanni Barosi and Vannucchi, {Alessandro M.}",
year = "2008",
month = "9",
doi = "10.2353/jmoldx.2008.080015",
language = "English",
volume = "10",
pages = "435--441",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "5",

}

TY - JOUR

T1 - A sensitive detection method for WPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction

AU - Pancrazzi, Alessandro

AU - Guglielmelli, Paola

AU - Ponziani, Vanessa

AU - Bergamaschi, Gaetano

AU - Bosi, Alberto

AU - Barosi, Giovanni

AU - Vannucchi, Alessandro M.

PY - 2008/9

Y1 - 2008/9

N2 - Acquired mutations in the juxtamembrane region of MPL (W515K or W515L), the receptor for thrombo-poietin, have been described in patients with primary myelofibrosis or essential thrombocythemia, which are chronic myeloproliferative disorders. We have developed a real-time polymerase chain reaction assay for the detection and quantification of MPL mutations that is based on locked nucleic acid fluorescent probes. Mutational analysis was performed using DNA from granulocytes. Reference curves were obtained using cloned fragments of MPL containing either the wild-type or mutated sequence; the predicted sensitivity level was at least 0.1% mutant allele in a wild-type background. None of the 60 control subjects presented with a MPLW515L/K mutation. Of 217 patients with myelofibrosis, 19 (8.7%) harbored the MPLW515 mutation, 10 (52.6%) with the W515L allele. In one case, both the W515L and W515K alleles were detected by real-time polymerase chain reaction. By comparing results obtained with conventional sequencing, no erroneous genotype attribution using real-time polymerase chain reaction was found, whereas one patient considered wild type according to sequence analysis actually harbored a low W515L allele burden. This is a simple, sensitive, and cost-effective procedure for large-scale screening of the MPLW515L/K mutation in patients suspected to have a myeloproliferative disorder. It can also provide a quantitative estimate of mutant allele burden that might be useful for both patient prognosis and monitoring response to therapy.

AB - Acquired mutations in the juxtamembrane region of MPL (W515K or W515L), the receptor for thrombo-poietin, have been described in patients with primary myelofibrosis or essential thrombocythemia, which are chronic myeloproliferative disorders. We have developed a real-time polymerase chain reaction assay for the detection and quantification of MPL mutations that is based on locked nucleic acid fluorescent probes. Mutational analysis was performed using DNA from granulocytes. Reference curves were obtained using cloned fragments of MPL containing either the wild-type or mutated sequence; the predicted sensitivity level was at least 0.1% mutant allele in a wild-type background. None of the 60 control subjects presented with a MPLW515L/K mutation. Of 217 patients with myelofibrosis, 19 (8.7%) harbored the MPLW515 mutation, 10 (52.6%) with the W515L allele. In one case, both the W515L and W515K alleles were detected by real-time polymerase chain reaction. By comparing results obtained with conventional sequencing, no erroneous genotype attribution using real-time polymerase chain reaction was found, whereas one patient considered wild type according to sequence analysis actually harbored a low W515L allele burden. This is a simple, sensitive, and cost-effective procedure for large-scale screening of the MPLW515L/K mutation in patients suspected to have a myeloproliferative disorder. It can also provide a quantitative estimate of mutant allele burden that might be useful for both patient prognosis and monitoring response to therapy.

UR - http://www.scopus.com/inward/record.url?scp=52249100940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249100940&partnerID=8YFLogxK

U2 - 10.2353/jmoldx.2008.080015

DO - 10.2353/jmoldx.2008.080015

M3 - Article

C2 - 18669880

AN - SCOPUS:52249100940

VL - 10

SP - 435

EP - 441

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 5

ER -